MEwens
Also: food-safety bill hits a snag; Allergan seeks broader (though thinner) audience for Lap-Band; PhRMA dollars; Merck bets on experimental insulin product.
Read more this great post here
Continued Read ...
MEwens
Software systems that manage billing and reimbursement are in demand, and deals are following.
Read more this great post here
Continued Read ...
Katherine Hobson
Also: shopping psychology; Merck’s Vytorin gets some positive data; ER visits for young kids’ cough and cold reactions drop.
Read more this great post here
Continued Read ...
Katherine Hobson
Pfizer said in a regulatory filing it would exceed the 15% job-cut target associated with its 2009 purchase of Wyeth.
Read more this great post here
Continued Read ...
MEwens
Also: FDA makes CT scanning recs; medical groups say it’s okay to mix Plavix and GI drugs in certain patients; high-deductible plans may discourage preventive care.
Read more this great post here
Continued Read ...
Katherine Hobson
Pfizer’s results — and management’s rosy outlook — depended heavily on Wyeth.
Read more this great post here
Continued Read ...
WSJ Staff
The future of the drug in MS treatment has become a key component of Genzyme’s rejection of an $18.5 billion hostile takeover offer from Sanofi-Aventis as too low.
Read more this great post here
Continued Read ...
Thomas Gryta
A Massachusetts judge has just signed off on a deal that lets a division of Cerberus Capital Management take over Bostons Caritas Christi Health Care System.
Read more this great post here
Continued Read ...
Katherine Hobson
Also: food makers to offer new front-of-package label; Glaxo whistleblower; Harvard Med School gets $30 million for primary care.
Read more this great post here
Continued Read ...
MEwens
Also: a report that Walgreen is looking to sell PBM; the difficulty of weight-loss drug development; hormones and pets.
Read more this great post here
Continued Read ...
